STAT+: ‘Can’t get much worse:’ What a European rejection of an Alzheimer’s drug would mean for Biogen

In a potentially huge setback for Biogen (BIIB), a European regulatory panel signaled that it is unlikely to recommend the company’s controversial Alzheimer’s treatment should be approved. And while a final decision by the European Medicines Agency will not be known until next month, Wall Street is quickly discounting the possibility the medication will generate revenues from the vast European market.

The move comes amid intensifying pressure on Biogen.

Continue to STAT+ to read the full story…